
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson has experienced a notable acceleration in its revenue growth, increasing from 3–4% in the 2016–2019 period to 6.1% in 2022 and 7.8% in 2023, reflecting the company's successful focus on innovation and productivity. The company’s pharmaceutical division, bolstered by an expanding product pipeline, particularly in immunology and oncology, is expected to contribute to sustained revenue growth as indicated by high clinical remission rates from its therapies. Additionally, Johnson & Johnson remains attractively valued, trading in line with historical multiples despite its enhanced financial profile following the divestment of its consumer business.
Bears say
Johnson & Johnson's stock outlook appears negative primarily due to several critical factors impacting its future revenue potential. The company faces a significant risk from loss of exclusivity on key drugs, which could result in lower-than-expected organic revenue growth, and concerns regarding the uptake of MedTech products amidst competitive pressures. Additionally, ongoing litigations and the financial implications of the Inflation Reduction Act present further risks that could hinder performance and disrupt operations, complicating its path for sustainable growth in the near future.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares